CD81 通过阻断 CD274/PD-L1 的选择性自噬降解驱动放射抵抗性胶质母细胞瘤的免疫逃逸
CD81 drives immune evasion in radioresistant glioblastoma by blocking selective autophagic degradation of CD274/PD-L1.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
胶质母细胞瘤中的 TIL（肿瘤浸润淋巴细胞）：免疫生物学与转化意义
英文原题：Tumor infiltrating lymphocytes in glioblastoma: immunobiology and translational implications.
查看英文原题
Tumor infiltrating lymphocytes in glioblastoma: immunobiology and translational implications.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
胶质母细胞瘤（GBM）由于其低肿瘤突变负荷、深刻的抗原异质性和高度免疫抑制的微环境，给免疫治疗带来了独特的挑战。人类 GBM 中TIL（肿瘤浸润淋巴细胞）的观察结果与同源原位鼠模型中的不同：虽然几种广泛使用的鼠神经胶质瘤模型中的 TIL 显示出大量耗尽的 T 细胞，但患者肿瘤中富含功能不确定的克隆扩增的颗粒酶 K T 细胞。我们回顾了目前对 GBM 中脑肿瘤免疫周期的理解，强调了 TIL 生物学的转化意义，并评估了新兴的基于 TCR 的方法，包括过继性 TIL 转移、新抗原疫苗和工程化受体。专注于识别和利用肿瘤选择性 T 细胞可能会为 GBM 提供更合理、个性化的免疫疗法。
展开英文摘要原文
Glioblastoma (GBM) poses unique challenges to immunotherapy, owing to its low tumor mutational burden, profound antigenic heterogeneity, and highly immunosuppressive microenvironment. Observations of tumor-infiltrating lymphocytes (TILs) in human GBM differ from those in syngeneic orthotopic murine models: whereas TILs in several widely used murine glioma models display an abundance of exhausted T cells, patient tumors are enriched for clonally expanded granzyme K T cells of uncertain function.
We review the current understanding of the brain tumor immunity cycle in GBM, highlight the translational implications of TIL biology, and evaluate emerging TCR-based approaches, including adoptive TILs transfer, neoantigen vaccines, and engineered receptors. A refined focus on identifying and harnessing tumor-selective T cells may enable more rational, personalized immunotherapies for GBM.
论文信息
- 作者
- Hill CM、Nwagwu CD、Odukoya AO、Hsueh B、Wang AZ、Dunn GP
- 第一作者单位
- Brain Tumor Immunology and Immunotherapy Program, Department of Neurosurgery, Massachusetts General Hospital, Boston, MA, USA.United States
- 通讯作者单位
- Brain Tumor Immunology and Immunotherapy Program, Department of Neurosurgery, Massachusetts General Hospital, Boston, MA, USA. gpdunn@mgh.harvard.edu.United States
- 文献类型
- 综述
- 期刊
- NPJ precision oncology2026 Jul 13
- 原文标识
- PubMed 42437767 · DOI 10.1038/s41698-026-01330-3
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →